Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003 Lung Function Profile in COPD
NCT02347072Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of BEVESPI AEROSPHERE in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Pearl Therapeutics. Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve 0-24 at Day 29. Started Feb 2015; status: completed.
02
Drugs
BEVESPI AEROSPHERE
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02347072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347072.